{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T17:54:00Z","timestamp":1777139640448,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,2,3]],"date-time":"2013-02-03T00:00:00Z","timestamp":1359849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s11934-013-0312-2","type":"journal-article","created":{"date-parts":[[2013,2,2]],"date-time":"2013-02-02T04:43:49Z","timestamp":1359780229000},"page":"65-70","source":"Crossref","is-referenced-by-count":9,"title":["Experience with Newer Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer"],"prefix":"10.1007","volume":"14","author":[{"given":"LaMont J.","family":"Barlow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell C.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,3]]},"reference":[{"key":"312_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10\u201329.","journal-title":"CA Cancer J Clin"},{"key":"312_CR2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0022-5347(17)42387-1","volume":"139","author":"H Rubben","year":"1988","unstructured":"Rubben H, Lutzeyer W, Fischer N, et al. Natural history and treatment of low and high risk superficial bladder tumors. J Urol. 1988;139:283\u20135.","journal-title":"J Urol"},{"key":"312_CR3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116:180\u20133.","journal-title":"J Urol"},{"key":"312_CR4","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0022-5347(17)53354-6","volume":"128","author":"DL Lamm","year":"1982","unstructured":"Lamm DL, Reichert DF, Harris SC, Lucio RM. Immunotherapy of murine transitional cell carcinoma. J Urol. 1982;128:1104\u20138.","journal-title":"J Urol"},{"key":"312_CR5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1365-2249.2003.02071.x","volume":"131","author":"R Nadler","year":"2003","unstructured":"Nadler R, Luo Y, Zhao W, et al. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity. Clin Exp Immunol. 2003;131:206\u201316.","journal-title":"Clin Exp Immunol"},{"key":"312_CR6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-5347(17)43909-7","volume":"137","author":"TL Ratliff","year":"1987","unstructured":"Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol. 1987;137:155\u20138.","journal-title":"J Urol"},{"key":"312_CR7","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","volume":"150","author":"TL Ratliff","year":"1993","unstructured":"Ratliff TL, Ritchey JK, Yuan JJ, et al. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 1993;150:1018\u201323.","journal-title":"J Urol"},{"key":"312_CR8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1464-410X.1998.00720.x","volume":"82","author":"NA Mungan","year":"1998","unstructured":"Mungan NA, Witjes JA. Bacille Calmette-Guerin in superficial transitional cell carcinoma. Br J Urol. 1998;82:213\u201323.","journal-title":"Br J Urol"},{"key":"312_CR9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","volume":"170","author":"A Bohle","year":"2003","unstructured":"Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol. 2003;170:964\u20139.","journal-title":"J Urol"},{"key":"312_CR10","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","volume":"64","author":"AT Ludwig","year":"2004","unstructured":"Ludwig AT, Moore JM, Luo Y, et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res. 2004;64:3386\u201390.","journal-title":"Cancer Res"},{"key":"312_CR11","first-page":"2447","volume-title":"Campbell-Walsh urology, 9 edn, vol. 3","author":"J Jones","year":"2006","unstructured":"Jones J, Campbell S. Non-muscle-invasive bladder cancer (Ta, T1, and CIS). In: Wein A, Kavoussi L, Novick A, Partin A, Peters C, editors. Campbell-Walsh urology, 9 edn, vol. 3. Philadelphia: Saunders; 2006. p. 2447\u201367."},{"key":"312_CR12","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0022-5347(01)65673-8","volume":"156","author":"S Krege","year":"1996","unstructured":"Krege S, Giani G, Meyer R, et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating clinics. J Urol. 1996;156:962\u20136.","journal-title":"J Urol"},{"key":"312_CR13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-5347(17)49690-X","volume":"132","author":"A Morales","year":"1984","unstructured":"Morales A. Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer. J Urol. 1984;132:457\u20139.","journal-title":"J Urol"},{"key":"312_CR14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","volume":"137","author":"WJ Catalona","year":"1987","unstructured":"Catalona WJ, Hudson MA, Gillen DP, et al. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol. 1987;137:220\u20134.","journal-title":"J Urol"},{"key":"312_CR15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1101\/gad.1772909","volume":"23","author":"AM Puzio-Kuter","year":"2009","unstructured":"Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 2009;23:675\u201380.","journal-title":"Genes Dev"},{"key":"312_CR16","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","volume":"169","author":"HW Herr","year":"2003","unstructured":"Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol. 2003;169:1706\u20138.","journal-title":"J Urol"},{"key":"312_CR17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.2007.06912.x","volume":"100","author":"EH Lambert","year":"2007","unstructured":"Lambert EH, Pierorazio PM, Olsson CA, et al. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int. 2007;100:33\u20136.","journal-title":"BJU Int"},{"key":"312_CR18","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.juro.2008.11.019","volume":"181","author":"A Morales","year":"2009","unstructured":"Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J Urol. 2009;181:1040\u20135.","journal-title":"J Urol"},{"key":"312_CR19","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","volume":"161","author":"PU Malmstrom","year":"1999","unstructured":"Malmstrom PU, Wijkstrom H, Lundholm C, et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol. 1999;161:1124\u20137.","journal-title":"J Urol"},{"key":"312_CR20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","volume":"28","author":"R Addeo","year":"2009","unstructured":"Addeo R, Caraglia M, Bellini S, et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2009;28:543\u20138.","journal-title":"J Clin Oncol"},{"key":"312_CR21","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","volume":"52","author":"MG Friedrich","year":"2007","unstructured":"Friedrich MG, Pichlmeier U, Schwaibold H, et al. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol. 2007;52:1123\u20139.","journal-title":"Eur Urol"},{"key":"312_CR22","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0090-4295(96)00621-8","volume":"49","author":"RE Greenberg","year":"1997","unstructured":"Greenberg RE, Bahnson RR, Wood D, et al. Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology. 1997;49:471\u20135.","journal-title":"Urology"},{"key":"312_CR23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0090-4295(00)00654-3","volume":"56","author":"AL Patterson","year":"2000","unstructured":"Patterson AL, Greenberg RE, Weems L, et al. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology. 2000;56:232\u20135.","journal-title":"Urology"},{"key":"312_CR24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","volume":"163","author":"G Steinberg","year":"2000","unstructured":"Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000;163:761\u20137.","journal-title":"J Urol"},{"key":"312_CR25","doi-asserted-by":"crossref","unstructured":"\u2022 Dinney CP, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin. Urol Oncol 2012, doi: 10.1016\/j.urolonc.2012.04.010 . The authors report the long-term recurrence data from a combined phase II\/III trial of intravesical valrubicin.","DOI":"10.1016\/j.urolonc.2012.04.010"},{"key":"312_CR26","doi-asserted-by":"crossref","unstructured":"The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer. Br J Urol. 1985;57:680\u201385.","DOI":"10.1111\/j.1464-410X.1985.tb07031.x"},{"key":"312_CR27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0090-4295(85)90249-3","volume":"26","author":"NM Heney","year":"1985","unstructured":"Heney NM. First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa. Urology. 1985;26:27\u20139.","journal-title":"Urology"},{"key":"312_CR28","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0022-5347(17)42052-0","volume":"140","author":"NM Heney","year":"1988","unstructured":"Heney NM, Koontz WW, Barton B, et al. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. J Urol. 1988;140:1390\u20133.","journal-title":"J Urol"},{"key":"312_CR29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0094-0143(21)00419-5","volume":"19","author":"JB Thrasher","year":"1992","unstructured":"Thrasher JB, Crawford ED. Complications of intravesical chemotherapy. Urol Clin N Am. 1992;19:529\u201339.","journal-title":"Urol Clin N Am"},{"key":"312_CR30","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","volume":"66","author":"R Bartoletti","year":"2005","unstructured":"Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology. 2005;66:726\u201331.","journal-title":"Urology"},{"key":"312_CR31","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","volume":"24","author":"G Dalbagni","year":"2006","unstructured":"Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24:2729\u201334.","journal-title":"J Clin Oncol"},{"key":"312_CR32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2004.08.027","volume":"65","author":"V Serretta","year":"2005","unstructured":"Serretta V, Galuffo A, Pavone C, et al. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: phase I-II study on marker lesions. Urology. 2005;65:65\u20139.","journal-title":"Urology"},{"key":"312_CR33","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","volume":"20","author":"G Dalbagni","year":"2002","unstructured":"Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol. 2002;20:3193\u20138.","journal-title":"J Clin Oncol"},{"key":"312_CR34","first-page":"281","volume":"10","author":"HB Grossman","year":"2008","unstructured":"Grossman HB, O\u2019Donnell MA, Cookson MS, et al. Bacillus calmette-guerin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Rev Urol. 2008;10:281\u20139.","journal-title":"Rev Urol"},{"key":"312_CR35","first-page":"CD009294","volume":"1","author":"G Jones","year":"2012","unstructured":"\u2022\u2022 Jones G, Cleves A, Wilt TJ, et al. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2012;1:CD009294. This is a comprehensive review of randomized controlled trials of intravesical gemcitabine. It includes 704 patients from six studies.","journal-title":"Cochrane Database Syst Rev"},{"key":"312_CR36","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.1997.15.12.3441","volume":"15","author":"MJ Moore","year":"1997","unstructured":"Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997;15:3441\u20135.","journal-title":"J Clin Oncol"},{"key":"312_CR37","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","volume":"15","author":"WM Stadler","year":"1997","unstructured":"Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997;15:3394\u20138.","journal-title":"J Clin Oncol"},{"key":"312_CR38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/CAD.0b013e3283324d83","volume":"21","author":"S Perdona","year":"2010","unstructured":"Perdona S, Di Lorenzo G, Cantiello F, et al. Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. Anticancer Drugs. 2010;21:101\u20136.","journal-title":"Anticancer Drugs"},{"key":"312_CR39","unstructured":"Skinner EC, Goldman B, Sakr WA, et al. SWOG S0353: phase II trial of intravesical gemcitabine in patients with non-muscle invasive bladder cancer who recurred following at least two prior courses of BCG. 2012 American Urological Association Annual Meeting; 2012. May 22nd; Atlanta, Georgia, 2012."},{"key":"312_CR40","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00345-002-0275-2","volume":"20","author":"F Calabro","year":"2002","unstructured":"Calabro F, Sternberg CN. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol. 2002;20:158\u201366.","journal-title":"World J Urol"},{"key":"312_CR41","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s002800050660","volume":"40","author":"D Song","year":"1997","unstructured":"Song D, Wientjes MG, Au JL. Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol. 1997;40:285\u201392.","journal-title":"Cancer Chemother Pharmacol"},{"key":"312_CR42","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","volume":"24","author":"JM McKiernan","year":"2006","unstructured":"McKiernan JM, Masson P, Murphy AM, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol. 2006;24:3075\u201380.","journal-title":"J Clin Oncol"},{"key":"312_CR43","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2009.06.112","volume":"75","author":"MA Laudano","year":"2009","unstructured":"Laudano MA, Barlow LJ, Murphy AM, et al. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology. 2009;75:134\u20137.","journal-title":"Urology"},{"key":"312_CR44","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1464-410X.2009.08543.x","volume":"104","author":"L Barlow","year":"2009","unstructured":"Barlow L, McKiernan J, Sawczuk I, Benson M. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guerin therapy. BJU Int. 2009;104:1098\u2013102.","journal-title":"BJU Int"},{"key":"312_CR45","unstructured":"Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel in the management of non-muscle-invasive bladder cancer (NMIBC) refractory to BCG therapy. 2012 American Urological Association Annual Meeting; 2012. May 22nd; Atlanta, Georgia, 2012."},{"key":"312_CR46","doi-asserted-by":"crossref","unstructured":"\u2022 Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with Intravesical Docetaxel in the management of recurrent nonmuscle invasive bladder cancer after previous Bacillus Calmette-Guerin therapy. J Urol. 2012, doi: 10.1016\/j.juro.2012.10.068 . This is the largest published series of intravesical docetaxel. It includes long-term recurrence and survival outcomes as well as the impact of maintenance docetaxel on delaying recurrence.","DOI":"10.1016\/j.juro.2012.10.068"},{"key":"312_CR47","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","volume":"166","author":"HW Herr","year":"2001","unstructured":"Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol. 2001;166:1296\u20139.","journal-title":"J Urol"},{"key":"312_CR48","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","volume":"11","author":"A Sparreboom","year":"2005","unstructured":"Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res. 2005;11:4136\u201343.","journal-title":"Clin Cancer Res"},{"key":"312_CR49","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794\u2013803.","journal-title":"J Clin Oncol"},{"key":"312_CR50","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.juro.2011.03.129","volume":"186","author":"JM McKiernan","year":"2011","unstructured":"McKiernan JM, Barlow LJ, Laudano MA, et al. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer. J Urol. 2011;186:448\u201351.","journal-title":"J Urol"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-013-0312-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-013-0312-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-013-0312-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T06:57:49Z","timestamp":1644217069000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-013-0312-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,3]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["312"],"URL":"https:\/\/doi.org\/10.1007\/s11934-013-0312-2","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,3]]}}}